Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC
Introduction: In general, malnutrition is associated with more treatment toxicity and shorter survival in patients with cancer, but little is known about its impact on limited-stage (LS) SCLC. We investigated whether nutritional status and weight loss were associated with treatment outcomes in a ran...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001346 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594134503784448 |
|---|---|
| author | Evgenia Taranova Marianne Aanerud, MD, PhD Tarje O. Halvorsen, MD, PhD Kristin T. Killingberg, MD, PhD Marit Slaaen, MD, PhD Bjørn H. Grønberg, MD, PhD |
| author_facet | Evgenia Taranova Marianne Aanerud, MD, PhD Tarje O. Halvorsen, MD, PhD Kristin T. Killingberg, MD, PhD Marit Slaaen, MD, PhD Bjørn H. Grønberg, MD, PhD |
| author_sort | Evgenia Taranova |
| collection | DOAJ |
| description | Introduction: In general, malnutrition is associated with more treatment toxicity and shorter survival in patients with cancer, but little is known about its impact on limited-stage (LS) SCLC. We investigated whether nutritional status and weight loss were associated with treatment outcomes in a randomized trial of thoracic radiotherapy (TRT) in LS SCLC (NCT02041845, N = 170). Methods: Patients received platinum-etoposide-chemotherapy and were randomized to receive TRT of 60 Gy in 40 fractions or 45 Gy in 30 fractions. They reported nutritional status on the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) and were categorized as having low (PG-SGA SF score 0–3), intermediate (score 4–8), or high (score ≥ 9) malnutrition risk. Results: In total, 113 patients who completed the PG-SGA SF at baseline and received one or more fractions of TRT were analyzed. Median PG-SGA SF score was 3.0; 52.2% had low, 29.2% intermediate, and 18.6% had high malnutrition risk; and 22.1% had 5% or more weight loss three months before enrolment. There were no significant differences in grade 3 to 4 toxicity (low: 88.1%, intermediate: 90.9%, high: 85.7%; p = 0.86), median progression-free survival (low: 15.8 months, intermediate: 11.8 months, high: 47.0 months; p = 0.25) or median OS (low: 35.5 months, intermediate: 26.8 months, high: 47.0 months; p = 0.24) across malnutrition categories. Weight loss was not significantly associated with grade 3 to 4 toxicity (≥5%: 92.0%, <5%: 87.0%; p = 0.73), median progression-free survival (≥5%: 24.0 months, <5%: 15.9 months; p = 0.51) or median OS (≥5%: 30.6 months, <5%: 35.5 months; p = 0.74). Conclusion: Patient-reported nutritional status and weight loss before concurrent chemoradiotherapy were neither associated with toxicity nor survival. |
| format | Article |
| id | doaj-art-4aa2e3da7cab4ced9b13bc1468a45e41 |
| institution | Kabale University |
| issn | 2666-3643 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-4aa2e3da7cab4ced9b13bc1468a45e412025-01-20T04:17:55ZengElsevierJTO Clinical and Research Reports2666-36432025-01-0161100764Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLCEvgenia Taranova0Marianne Aanerud, MD, PhD1Tarje O. Halvorsen, MD, PhD2Kristin T. Killingberg, MD, PhD3Marit Slaaen, MD, PhD4Bjørn H. Grønberg, MD, PhD5Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway; Corresponding author. Address for correspondence: Evgenia Taranova, Department of Clinical Science, University of Bergen, 5009 Bergen, Norway.Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwayDepartment of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim, NorwayDepartment of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim, NorwayThe Research Centre for Age-Related Functional Decline and Disease, Innlandet Hospital Trust, Ottestad, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, NorwayDepartment of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim, NorwayIntroduction: In general, malnutrition is associated with more treatment toxicity and shorter survival in patients with cancer, but little is known about its impact on limited-stage (LS) SCLC. We investigated whether nutritional status and weight loss were associated with treatment outcomes in a randomized trial of thoracic radiotherapy (TRT) in LS SCLC (NCT02041845, N = 170). Methods: Patients received platinum-etoposide-chemotherapy and were randomized to receive TRT of 60 Gy in 40 fractions or 45 Gy in 30 fractions. They reported nutritional status on the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) and were categorized as having low (PG-SGA SF score 0–3), intermediate (score 4–8), or high (score ≥ 9) malnutrition risk. Results: In total, 113 patients who completed the PG-SGA SF at baseline and received one or more fractions of TRT were analyzed. Median PG-SGA SF score was 3.0; 52.2% had low, 29.2% intermediate, and 18.6% had high malnutrition risk; and 22.1% had 5% or more weight loss three months before enrolment. There were no significant differences in grade 3 to 4 toxicity (low: 88.1%, intermediate: 90.9%, high: 85.7%; p = 0.86), median progression-free survival (low: 15.8 months, intermediate: 11.8 months, high: 47.0 months; p = 0.25) or median OS (low: 35.5 months, intermediate: 26.8 months, high: 47.0 months; p = 0.24) across malnutrition categories. Weight loss was not significantly associated with grade 3 to 4 toxicity (≥5%: 92.0%, <5%: 87.0%; p = 0.73), median progression-free survival (≥5%: 24.0 months, <5%: 15.9 months; p = 0.51) or median OS (≥5%: 30.6 months, <5%: 35.5 months; p = 0.74). Conclusion: Patient-reported nutritional status and weight loss before concurrent chemoradiotherapy were neither associated with toxicity nor survival.http://www.sciencedirect.com/science/article/pii/S2666364324001346Small-cell lung cancerChemoradiotherapyWeight-lossPG-SGA SFNutrition |
| spellingShingle | Evgenia Taranova Marianne Aanerud, MD, PhD Tarje O. Halvorsen, MD, PhD Kristin T. Killingberg, MD, PhD Marit Slaaen, MD, PhD Bjørn H. Grønberg, MD, PhD Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC JTO Clinical and Research Reports Small-cell lung cancer Chemoradiotherapy Weight-loss PG-SGA SF Nutrition |
| title | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC |
| title_full | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC |
| title_fullStr | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC |
| title_full_unstemmed | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC |
| title_short | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC |
| title_sort | associations between patient reported nutritional status toxicity and survival in limited stage sclc |
| topic | Small-cell lung cancer Chemoradiotherapy Weight-loss PG-SGA SF Nutrition |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324001346 |
| work_keys_str_mv | AT evgeniataranova associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc AT marianneaanerudmdphd associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc AT tarjeohalvorsenmdphd associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc AT kristintkillingbergmdphd associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc AT maritslaaenmdphd associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc AT bjørnhgrønbergmdphd associationsbetweenpatientreportednutritionalstatustoxicityandsurvivalinlimitedstagesclc |